18+ · Research use only
Semaglutide · Phase 3 · Completed
STEP 2
In STEP 2, a phase 3 trial of semaglutide in adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening (n=1,210), mean body weight fell 9.6% on 2.4 mg over 68 weeks, against 3.4% on placebo (Davies M et al. Lancet 2021 (STEP 2)).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Updated 24 September 2026
Results
Side effects reported
The most frequently reported adverse events were gastrointestinal adverse events in 63.5% on 2.4 mg and 57.5% on 1.0 mg against 34.3% on placebo.
| Event | 2.4 mg | 1.0 mg | Placebo |
|---|---|---|---|
| Gastrointestinal adverse events | 63.5% | 57.5% | 34.3% |
Design
Trial design and sources
- Compound
- Semaglutide
- Phase
- 3
- Population
- Adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening
- Participants randomised
- 1,210
- Duration
- 68 weeks
- Primary endpoint
- Coprimary: percentage change in bodyweight and achievement of weight reduction of at least 5% at 68 weeks, semaglutide 2.4 mg versus placebo
- Estimand
- Not stated in the source read
- Read out
- 2 March 2021
The abstract gives no body-weight figure for the 1.0 mg arm and does not name the estimand (intention to treat).
Questions
STEP 2, answered
What did STEP 2 find?
In STEP 2, a phase 3 trial of semaglutide in adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening (n=1,210), mean body weight fell 9.6% on 2.4 mg over 68 weeks, against 3.4% on placebo (Davies M et al. Lancet 2021 (STEP 2)).
What side effects were reported in STEP 2?
The most frequently reported adverse events were gastrointestinal adverse events in 63.5% on 2.4 mg and 57.5% on 1.0 mg against 34.3% on placebo.
Related